Pre-Open 10/03: (PBYI) (EPRT) (CLF(=) Higher (GPRO) (AXTI) (JKHY) Lower (more...)
- S&P hits record, Nasdaq jumps 1% as weak jobs data eases Fed tapering worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar slides to more than two-month low after big U.S. jobs miss
- Square (SQ) Tops Q1 EPS by 25c
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
GoPro (NASDAQ: GPRO) 16.5% LOWER; FY EPS Guidance Misses Consensus
AXT, Inc. (NasdaqGS: AXTI) 15.1% LOWER; The company now expects third quarter revenue to be in the range of $19.6 million to $20.0 million, due to a weaker than expected demand environment, particularly in data center connectivity and LED applications. In addition, raw material revenue was also lower than forecasted. The revised revenue expectation is down from the companys previous guidance of $24.5 million to $26 million, provided at its second quarter earnings announcement on July 24, 2019. (*Consensus calls for Q3 revenue of $25.4 million)
Puma Biotechnology, Inc. (NASDAQ: PBYI) 11% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement for NERLYNX® (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. With the approval of the labeling supplement, the label now includes safety information based on interim results from Pumas Phase II CONTROL Trial, a study evaluating antidiarrheal prophylaxis or dose escalation in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 or higher diarrhea. Interim data from the trial showed that the addition of prophylactic treatment with loperamide plus budesonide reduced the discontinuation rate due to neratinib-associated diarrhea to 11% versus a discontinuation rate of 18% with loperamide alone.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 6.6% HIGHER; announced today that the Company’s permanent and specific J-Code for YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the Centers for Medicare and Medicaid Services (CMS) one quarter earlier than under prior CMS policy.
AngioDynamics (NASDAQ: ANGO) 6% LOWER; reported Q1 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $66 million versus the consensus estimate of $67.52 million. AngioDynamics sees FY2020 EPS of $0.10-$0.15, versus the consensus of $0.26. AngioDynamics sees FY2020 revenue of $280-296 million, versus the consensus of $281.98 million.
Tesla (Nasdaq: TSLA) 5.2% LOWER; announced that in the third quarter, they achieved record production of 96,155 vehicles and record deliveries of approximately 97,000 vehicles.
Cleveland-Cliffs Inc. (NYSE: CLF) 4.9% HIGHER; will replace Mercury Systems in the S&P SmallCap 600
CrowdStrike Holdings (NASDAQ: CRWD) 4.5% HIGHER; SunTrust upgrades from Hold to Buy, price target $80.00.
City Office REIT, Inc. (NYSE: CIO) 4% LOWER; announced today that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock.
Constellation Brands (NYSE: STZ) 3.7% LOWER; reported Q2 EPS of $2.72, $0.12 better than the analyst estimate of $2.60. Revenue for the quarter came in at $2.34 billion versus the consensus estimate of $2.34 billion. Constellation Brands sees FY2020 EPS of $9.00-$9.20, versus the consensus of $8.43.
Arista Networks (NYSE: ANET) 2.8% LOWER; Nomura/Instinet downgraded from Buy to Neutral with a price target of $230.00 (from $290.00).
PepsiCo (NASDAQ: PEP) 2.2% HIGHER; reported Q3 EPS of $1.56, $0.06 better than the analyst estimate of $1.50. Revenue for the quarter came in at $17.2 billion versus the consensus estimate of $16.93 billion. PepsiCo sees FY2019 EPS of $5.50, versus the consensus of $5.52.
FireEye, Inc. (NASDAQ: FEYE) 2% HIGHER; UBS sees SOTP value at $22/share in a takeout
Bed Bath & Beyond (NASDAQ: BBBY) 1.7% LOWER; reported Q2 EPS of $0.34, $0.07 better than the analyst estimate of $0.27. Revenue for the quarter came in at $2.7 billion versus the consensus estimate of $2.75 billion. Comparable sales in the fiscal 2019 second quarter declined approximately 6.7%. Bed Bath & Beyond sees FY2019 EPS of $2.08-$2.13, versus the consensus of $1.86. Bed Bath & Beyond sees FY2019 revenue of $11.4 billion, versus the consensus of $11.36 billion.
E*TRADE Financial Corporation (NASDAQ: ETFC) 0.8% HIGHER; announced it will eliminate retail commissions for online US listed stock, ETF, and options trades. It will also reduce the options contract charge to $0.65 per contract for all traders while maintaining its active trader pricing at $0.50 per contract. These changes will take effect on October 7, 2019.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 05/07: (IBIO) (BILL) (AXON) Higher; (CCIX) (APPN) (FROG) Lower (more...)
- Navitas Semiconductor to Go Public at Enterprise Value of $1.04 Billion via Live Oak II (LOKB)
- Pre-Open Movers 05/05: (CHMA) (ATNX) (IBIO) Higher; (COCP) (ESPR) (MCFE) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesUBS, Standard & Poor's, Nomura, Tesla, Earnings, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!